Novel MRI Sequences for Prostate Cancer Diagnosis Accuracy: NCT07552285
Summary
NCT07552285 is a prospective observational study registered at a single center evaluating the diagnostic efficacy and grading accuracy of novel MRI sequences (MAGiC, OGSE, CEST, IVIM) for prostate cancer detection. The study enrolls patients with clinical suspicion of prostate cancer and performs both conventional and new sequence magnetic resonance scans, using surgical or biopsy pathological results as the gold standard for comparison. The primary research question is whether novel non-contrast multiparametric MRI imaging can improve accuracy of prostate cancer diagnosis and grading compared to conventional approaches.
“Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer?”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07552285 registers a prospective observational clinical trial examining whether novel MRI sequences can improve diagnostic accuracy and grading of prostate cancer compared to conventional imaging. The study employs multiparametric MRI techniques including MAGiC, OGSE, CEST, and IVIM, with pathological findings from biopsy or surgery serving as the reference standard. Patients with clinical suspicion of prostate cancer undergo both conventional and experimental MRI protocols for direct comparison.
Healthcare providers and clinical investigators involved in prostate cancer diagnostics should note this study evaluates next-generation non-contrast MRI approaches that may eventually complement or reduce reliance on contrast-enhanced imaging. The trial focuses on diagnostic and grading efficacy, addressing a key area in prostate cancer detection where improved accuracy could affect biopsy decisions and treatment planning.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
Observational NCT07552285 Kind: OBSERVATIONAL Apr 27, 2026
Abstract
The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is:
Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.
Conditions: Prostate Cancer, Prostate Cancer (Diagnosis)
Interventions: observational study
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.